John McAdory was named Chief Operating Officer of Oncolytics Biotech Inc. As of November 6, 2026, Oncolytics Biotech Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on June 2, 2026, naming 2 appointments (Form 8-K, June 2, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Oncolytics Biotech Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Oncolytics Biotech Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-06-02. It names 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Oncolytics Biotech Inc files it.
Also on the record for Oncolytics Biotech Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 14, 2025 | Stake report, Schedule 13G/A, by Anson Funds Management LP | 7% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Oncolytics Biotech Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Oncolytics Biotech Inc and the records around it.
Oncolytics Biotech Inc elsewhere on the record
- 5%+ stake filings Nov 2025
Companies that share a holder
- Anson Funds Management LP also filed stake reports on 36 other companies: 22nd Century Group, Inc. (Aug 2026), Imperial Petroleum Inc. (Aug 2026), K Wave Media Ltd. (Aug 2026)
Watch Oncolytics Biotech Inc
Get an email when Oncolytics Biotech Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Oncolytics Biotech Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Oncolytics Biotech Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Oncolytics Biotech Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-02 | In | Chief Operating Officer | 8-K, 2026-06-02 | ||
| 2026-06-02 | In | Director | 8-K, 2026-06-02 |
Who leads Oncolytics Biotech Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Stephen Glover, appointed (filed 2026-06-02).
- Chief Operating Officer: John McAdory, appointed (filed 2026-06-02).
New leaders reset buying decisions — get the Full Report on Oncolytics Biotech Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Operating Officer at Oncolytics Biotech Inc, with the record behind each one.
Find candidates like Chief Operating Officer at Oncolytics Biotech IncEvery change, in the filing's words
Appointed: John McAdory, Chief Operating Officer
On June 1, 2026, the Board of Directors (the "Board") of Oncolytics Biotech Inc. (the "Company") appointed John McAdory as Chief Operating Officer of the Company.
Appointed: Stephen Glover, Director
Appointment of New Director Furthermore, on June 1, 2026, the Board, acting under a unanimous written consent, appointed Stephen Glover as the ninth director of the Board.
- Mr. McAdory will not receive any additional compensation as a result of the appointment.
- Mr. McAdory, age 49, has been appointed Chief Operating Officer of the Company, effective June 1, 2026.
- Mr. McAdory previously served as Executive Vice President, Strategy and Operations of the Company from January 2026 to June 2026.
- From January 2020 to January 2026, Mr. McAdory served as Vice President, Clinical Operations at CG Oncology, Inc. (Nasdaq: CGON), where he led clinical operations through its pivotal Phase 3 program and initial public offering.
- From February 2018 to January 2020, Mr. McAdory served as Head of Clinical Operations at SillaJen, Inc. Earlier in his career, Mr. McAdory held clinical operations positions at UCB and Amgen Inc. Mr. McAdory holds a Master of Health Administration from the University of North Carolina at Chapel Hill and a Bachelor of Science in Biology from Hampton University.
- Mr. Glover will serve as a director of the Company until the next annual meeting of the shareholders or until his successor shall have been elected and qualified subject to his earlier death, resignation, retirement, disqualification or removal.
Tools for this story
Each opens in a new tab, filled in for Oncolytics Biotech Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.